about
Controversies in measles immunization recommendations.Active immunization in the United States: developments over the past decade.A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy.Cross-sectional surveys of measles antibodies in the Jiangsu Province of China from 2008 to 2010: the effect of high coverage with two doses of measles vaccine among childrenFrequency of measles virus-specific CD4+ and CD8+ T cells in subjects seronegative or highly seropositive for measles vaccine.New York State's two-dose schedule for measles immunizationImmunoglobulin G avidity testing in serum and cerebrospinal fluid for analysis of measles virus infection.Measles control in the United States: problems of the past and challenges for the futureIdentification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic.Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccineAssociations between demographic variables and multiple measles-specific innate and cell-mediated immune responses after measles vaccination.Serological assessment of the establishment of herd immunity against measles in a health district in Malaysia.Persistence of antibodies induced by measles-mumps-rubella vaccine in children in IndiaExploring Human Antimicrobial Antibody Responses on a Single B Cell Level.Synonymous Deoptimization of Foot-and-Mouth Disease Virus Causes Attenuation In Vivo while Inducing a Strong Neutralizing Antibody Response.Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months.Childhood Vaccine Exemption Policy: The Case for a Less Restrictive AlternativeMeasles virus-specific cellular immunity in patients with vaccine failure.Performance Evaluation of the VIDAS(®) Measles IgG Assay and Its Diagnostic Value for Measuring IgG Antibody Avidity in Measles Virus Infection.Measles control--can measles virus inhibitors make a difference?Supplemental measles vaccine antibody response among HIV-infected and -uninfected children in Malawi after 1- and 2-dose primary measles vaccination schedules.Fever with Rash, an Alarm to the Physicians - A Case Report of Atypical Measles.Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.Efficacy of recombinant measles virus expressing highly pathogenic avian influenza virus (HPAIV) antigen against HPAIV infection in monkeys.Facebook and Twitter vaccine sentiment in response to measles outbreaks.Fatal Measles Virus Infection After Rituximab-Containing Chemotherapy in a Previously Vaccinated Patient
P2860
Q33606613-C1A1EFB9-809F-4659-B32E-5490A957185AQ33975799-AFF66C15-FEAF-47A5-9FD7-FDEDD8A9767CQ34454372-C0A3EB34-2B1D-4079-A4F3-061EFC1F972DQ34794244-0FFF2B25-8A1D-4325-8BEA-EF7C7244953FQ34996026-D7284373-998D-429A-A17C-0F6E231D15A3Q35055349-E3D04ADB-A05C-4C7B-82B5-892FDE887BC8Q35226116-809458BF-4365-42CF-AFDB-14C4FE485318Q35366326-AFCF5E2F-D98A-4B87-B4E3-354AEE7665ECQ35542471-05E9E995-749D-4050-8508-5EFF4328A9D4Q35558786-6EE5D883-E9AC-4BB8-8265-A6CE69A6DB68Q35731350-A236323C-DE71-414E-BD64-DCD94390A3B1Q36216474-9A1EC1D0-594A-498B-8E9E-73292ADF5BA8Q36313488-A7474809-B52B-4E73-AF85-EF1844F4E65BQ36327441-1E25B8E8-CC7E-4478-9018-3226BF3CFE9BQ36481497-50AF8658-F971-4341-8F3D-94453FDDE9A5Q36503931-CFB50B7A-5B92-4A35-92AA-5064F84FF0A9Q36738388-66A272C4-3788-4AAE-A80D-45AA3346D12BQ37060923-AB096531-F82E-4DD2-9C08-9672420121CFQ37203193-A525C042-8E40-49A1-8BA0-87C11036DBE3Q37570103-058C7640-FFCB-4A06-BB97-2D43D6A3AE0EQ39009658-BF166E40-3DF5-4FE1-ABF3-540E614CD420Q39246481-19086DC8-376C-4694-9B20-6D78C3518CB0Q40285941-E27927FA-B22C-4D84-B291-F5A4842A9C6EQ41696601-9B029B44-7050-4794-956B-AB954825E99DQ46264244-6A1D735C-5D8B-4092-85CA-D605464B066AQ58573668-6A3AE58F-E0A7-4998-B7F2-7148BD23959B
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Duration of live measles vaccine-induced immunity.
@en
Duration of live measles vaccine-induced immunity.
@nl
type
label
Duration of live measles vaccine-induced immunity.
@en
Duration of live measles vaccine-induced immunity.
@nl
prefLabel
Duration of live measles vaccine-induced immunity.
@en
Duration of live measles vaccine-induced immunity.
@nl
P2093
P1476
Duration of live measles vaccine-induced immunity.
@en
P2093
P304
P577
1990-02-01T00:00:00Z